Kun for helsepersonell

Søk 

Menu

Close

Logg innLogg ut
LegemiddelTerapiområdeUtforsk merUtforsk merMateriellVideo/podkastNyhetsbrevKontakt oss
OmAlopecia AreataLITFULO virkningsmekanismeSALT EvalueringEffektALLEGRO-2b/3 studieoversiktHårrespons i hodebunnenPasientrapporterte utfallØyenbryn og vipperesponsFør og etter bilderSikkerhetALLEGRO-2b/3 bivirkningerSamlede sikkerhetsdataYtterligere sikkerhetsinformasjonKom i gangDoseringScreening og oppfølgingSette pasientmålPasientprofilerOpplæringsmateriellMateriellVideo
ALLEGRO-2b/3 studieoversikt

Studiedesign

Baseline karakteristikker

Viktige studieendepunkt

Tab Number 4

Tab Number 5

The efficacy and safety of LITFULO were evaluated in the pivotal study, ALLEGRO-2b/31‐3

ALLEGRO-2b/3 was a randomised, double-blind, placebo-controlled, phase 2b/3 study in patients, aged 12 years and older (N=718), with alopecia areata and 50% or more scalp hair loss, including AT and AU. Patients were randomised to receive ritlecitinib or placebo once-daily for 24 weeks. After 24 weeks, all patients received ritlecitinib and there was no placebo control.*†
  • The primary endpoint was the proportion of patients with SALT score ≤10 at Week 24

  • The key secondary endpoint was the proportion of patients with a PGI-C response of “moderately” or “greatly” improved at Week 24‡
  • Safety was monitored throughout the study

  • Efficacy results include patients who received LITFULO 50 mg (the recommended daily dose)
Ritlecitinib doses included 30 mg and 50 mg, with or without a 200 mg loading dose, once a day for 4 weeks. Ritlecitinib 10 mg was included for pharmacokinetic, dose-response, and safety assessments only, and was not included in statistical comparisons vs placebo. The sample size for this study accounted for multiplicity using a closed testing procedure at Week 24 to ensure control of Type 1 error for all comparisons between active treatment groups and placebo, excluding the ritlecitinib 10 mg treatment group. The Patient's Global Impression of Change (PGI-C) is a self-administered questionnaire that asks patients to evaluate the improvement or worsening of their alopecia areata as compared to the start of the study. Responses of “moderately” or “greatly” improved were used as the patient-driven responder definition.What is SALT?

The Severity of Alopecia Tool (SALT) helps visually assess the extent of scalp hair loss.3,4

The SALT score equals the sum of the proportions of scalp hair loss per quadrant3

The SALT score measures hair loss on a scale of 0 (no scalp hair loss) to 100 (complete scalp hair loss). For example, SALT 10 can be defined as 10% scalp hair loss and/or 80% scalp hair coverage1,3

 See how LITFULO helped patients with alopecia areata Hårrespons i hodebunnenLoading

AT=alopecia totalis; AU=alopecia universalis; SALT=Severity of Alopecia Tool.

References:1. LITFULO (ritlecitinib) Summary of Product Characteristics. 2. King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial. Lancet. 2023;401(10387):1518-1529. doi:10.1016/S0140-6736(23)00222-2. Erratum in: Lancet. 2023 Jun 10; 401(10392):1928. 3. King B, Zhang X, Harcha WG, et al. Supplement to: Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial. Lancet. April 13, 2023. doi:10.1016/S0140-6736(23)00222-2
Selected baseline characteristics
Scroll left to view table
  LITFULO 50 mg (n=130) Placebo (n=131)
Age, n (%)    
       12 to 17 years 18 (14) 18 (14)
     ≥18 years 112 (86) 112 (86)
Female, n (%) 71 (55) 86 (66)
Race, n (%)    
     White 79 (61) 94 (72)
      Asian 43 (33) 31 (24)
AT/AU, n (%) 60 (46) 60 (46)
Mean SALT score (SD) 90.3 (14.7) 93 (11.5)
Mean non-AT/AU SALT 
score (SD)		 82 (15.9) 87 (12.9)
Abnormal eyebrows, n (%) 106 (82) 107 (82)
Abnormal eyelashes, n (%) 95 (73) 97 (74)
Mean duration since diagnosis, years (SD) 8.7 (8.7) 11 (11.8)
Mean duration of current episode, years (SD) 3.2 (2.7) 3.2 (2.7)
Key Inclusion Criteria1‐3
  • Male and female patients, 12 years of age or older*
  • Clinical diagnosis of alopecia areata
  • 50% or more scalp hair loss, including alopecia totalis or alopecia universalis
  • No evidence of terminal hair regrowth within 6 months, assessed at both the screening and baseline visits
  • Current episode of hair loss <10 years

Key Exclusion Criteria2,3

  • Other types of alopecia
  • Previous use of any JAK inhibitor
  • Any psychiatric condition, including clinically significant depression
  • Auditory conditions considered acute, fluctuating, or progressive
  • History of disseminated herpes zoster, disseminated herpes simplex, or recurrent localised, dermatomal herpes zoster
  • Patients aged 12 to <18 years without a documented history of varicella-zoster virus vaccination or presence of varicella-zoster virus IgG antibodies
Within Voluntary Harmonisation Procedure countries in the European Union, patients had to be between 18 and 74 years of age.What is SALT?

The Severity of Alopecia Tool (SALT) helps visually assess the extent of scalp hair loss.3,4

The SALT score equals the sum of the proportions of scalp hair loss per quadrant3

The SALT score measures hair loss on a scale of 0 (no scalp hair loss) to 100 (complete scalp hair loss). For example, SALT 10 can be defined as 10% scalp hair loss and/or 80% scalp hair coverage1,3

 See how LITFULO helped patients with alopecia areata Hårrespons i hodebunnenLoading

AT=alopecia totalis; AU=alopecia universalis; IgG=immunoglobulin; JAK=Janus kinase; SALT=Severity of Alopecia Tool; SD=standard deviation.

References:1. LITFULO (ritlecitinib) Summary of Product Characteristics. 2. King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial. Lancet. 2023;401(10387):1518-1529. doi:10.1016/S0140-6736(23)00222-2. Erratum in: Lancet. 2023 Jun 10; 401(10392):1928. 3. King B, Zhang X, Harcha WG, et al. Supplement to: Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial. Lancet. April 13, 2023. doi:10.1016/S0140-6736(23)00222-2
Key study endpoints1‐3
Scroll left to view table
Primary endpoint
  • For the EMA: Proportion of patients with a SALT score ≤10 (≥90% scalp hair coverage) vs placebo at Week 24*

  • For Overall study and FDA: The proportion of patients with SALT ≤20 (≥80% scalp hair coverage) at Week 24†
Key secondary endpoint For the EMA: Proportion of patients with a PGI-C score of "moderately" or "greatly" improved at Week 24‡
Additional secondary endpoints
  • Proportion of patients with a SALT score ≤10 (≥90% scalp hair coverage) through Week 48
  • Proportion of patients with a SALT score ≤20 (≥80% scalp hair coverage) through Week 48
  • Proportion of patients with ≥2-grade improvement from baseline, or with a score of 3, in eyebrows and eyelashes through Week 48
Based on a preestablished testing procedure at an overall significance level (α=0.01).Based on a preestablished testing procedure at an overall significance level for the overall study (α=0.05) and the FDA (α=0.00125).The Patient’s Global Impression of Change (PGI-C) is a self-administered questionnaire that asks the subject to evaluate the improvement or worsening of their alopecia areata as compared to the start of the study. Responses of “moderately” or “greatly” improved were used as the patient-driven responder definition. See how LITFULO helped patients with alopecia areata Hårrespons i hodebunnenLoading

EMA=European Medicines Agency; FDA=Food and Drug Administration; SALT=Severity of Alopecia Tool.

References:1. LITFULO (ritlecitinib) Summary of Product Characteristics. 2. King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial. Lancet. 2023;401(10387):1518-1529. doi:10.1016/S0140-6736(23)00222-2. Erratum in: Lancet. 2023 Jun 10; 401(10392):1928. 3. King B, Harcha WG, et al. Supplement to: Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial. Lancet. April 13, 2023 doi:10.1016/S0140-6736(23)00222-2
PP-LGF-NOR-0019 | Utarbeidet 08.2024
Effekt See how LITFULO helped patients with severe alopecia areata EffektLoading
Explore safety data SikkerhetLoading
Get appropriate patients started on LITFULO today Kom i gangLoading

Pfizer AS, Org.nr 915 213 596

Postadresse: Postboks 3, 1324 Lysaker
Besøksadresse: Drammensveien 288, 0283 Oslo

Tlf.: +47 67 52 61 00


PP-BCP-NOR-0001 juni 2023

Copyright © 2023 Pfizer AS. Innholdet er rettighetsbeskyttet.

 




 
Du forlater nå PfizerPro.no
Nettstedet du kommer til er hverken eid eller kontrollert av Pfizer i Norge. Pfizer i Norge er ikke ansvarlig for innholdet på nettstedet du kommer til.
Kun for helsepersonell

Dette nettstedet er kun for helsepersonell.

Jeg bekrefter at jeg er helsepersonell som definert i legemiddelforskriften §13-1.

Ved å velge "nei" vil du komme til Pfizer.no som er åpen for allmenheten.

Ja Nei